Advertisement
Screener

PHIO PHARMACEUTICALS CORP. (PHIO) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

PHIO PHARMACEUTICALS CORP. Research and Development Expense

PHIO PHARMACEUTICALS CORP. (PHIO) reported Research and Development Expense of $3.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06

  • PHIO PHARMACEUTICALS CORP. research and development expense for the quarter ending 2026-06-30 was $3.08M, a 186.96% increase year-over-year.
  • PHIO PHARMACEUTICALS CORP. research and development expense for the quarter ending 2026-03-31 was $2.79M, a 215.24% increase year-over-year.
  • PHIO PHARMACEUTICALS CORP. research and development expense for the quarter ending 2025-12-31 was $1.48M, a 49.95% increase year-over-year.
  • PHIO PHARMACEUTICALS CORP. research and development expense for the quarter ending 2025-09-30 was $1.18M, a 83.39% increase year-over-year.
  • PHIO PHARMACEUTICALS CORP. research and development expense for fiscal 2025 was $4.62M, a 26.76% increase from fiscal 2024.
  • PHIO PHARMACEUTICALS CORP. research and development expense for fiscal 2024 was $3.64M, a 42.47% decline from fiscal 2023.
  • PHIO PHARMACEUTICALS CORP. research and development expense for fiscal 2023 was $6.33M, a 9.70% decline from fiscal 2022.
  • PHIO PHARMACEUTICALS CORP. research and development expense for fiscal 2022 was $7.01M, a 21.09% decline from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filedResearch and Development Expense 114 monthResearch and Development Expense 117 monthResearch and Development Expense 120 month
2026-06-30$3.08M
10-Q · filed 2026-08-06
$5.87M
10-Q · filed 2026-08-06
$7.35M
derived: sum of 3 quarters · filed 2026-08-06
$8.53M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$2.79M
10-Q · filed 2026-05-07
$4.27M
derived: sum of 2 quarters · filed 2026-05-07
$5.45M
derived: sum of 3 quarters · filed 2026-05-07
$6.53M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$1.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$2.66M
derived: sum of 2 quarters · filed 2026-03-05
$3.73M
derived: sum of 3 quarters · filed 2026-08-06
$4.62M
10-K · filed 2026-03-05
2025-09-30$1.18M
10-Q · filed 2025-11-13
$2.25M
derived: sum of 2 quarters · filed 2026-08-06
$3.14M
10-Q · filed 2025-11-13
$4.13M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$1.07M
10-Q · filed 2026-08-06
$1.96M
10-Q · filed 2026-08-06
$2.94M
derived: sum of 3 quarters · filed 2026-08-06
$3.59M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$886.00K
10-Q · filed 2026-05-07
$1.87M
derived: sum of 2 quarters · filed 2026-05-07
$2.52M
derived: sum of 3 quarters · filed 2026-05-07
$3.38M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$985.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$1.63M
derived: sum of 2 quarters · filed 2026-03-05
$2.50M
derived: sum of 3 quarters · filed 2026-03-05
$3.64M
10-K · filed 2026-03-05
2024-09-30$644.00K
10-Q · filed 2025-11-13
$1.51M
derived: sum of 2 quarters · filed 2025-11-13
$2.66M
10-Q · filed 2025-11-13
$3.67M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$866.00K
10-Q · filed 2025-08-14
$2.01M
10-Q · filed 2025-08-14
$3.02M
derived: sum of 3 quarters · filed 2025-08-14
$4.83M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31$1.15M
10-Q · filed 2025-05-15
$2.15M
derived: sum of 2 quarters · filed 2025-05-15
$3.96M
derived: sum of 3 quarters · filed 2025-05-15
$5.35M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31$1.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$2.81M
derived: sum of 2 quarters · filed 2025-03-31
$4.20M
derived: sum of 3 quarters · filed 2025-03-31
$6.33M
10-K · filed 2025-03-31
2023-09-30$1.81M
10-Q · filed 2024-11-14
$3.19M
derived: sum of 2 quarters · filed 2024-11-14
$5.33M
10-Q · filed 2024-11-14
$6.94M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$1.38M
10-Q · filed 2024-08-14
$3.52M
10-Q · filed 2024-08-14
$5.13M
derived: sum of 3 quarters · filed 2024-08-14
$7.64M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31$2.13M
10-Q · filed 2024-05-09
$3.75M
derived: sum of 2 quarters · filed 2024-05-09
$6.26M
derived: sum of 3 quarters · filed 2024-05-09
$7.56M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$1.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$4.12M
derived: sum of 2 quarters · filed 2024-04-01
$5.43M
derived: sum of 3 quarters · filed 2024-04-01
$7.01M
10-K · filed 2024-04-01
2022-09-30$2.51M
10-Q · filed 2023-11-09
$3.81M
derived: sum of 2 quarters · filed 2023-11-09
$5.40M
10-Q · filed 2023-11-09
$7.62M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30$1.30M
10-Q · filed 2023-08-10
$2.89M
10-Q · filed 2023-08-10
$5.12M
derived: sum of 3 quarters · filed 2023-08-10
$7.79M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$1.59M
10-Q · filed 2023-05-11
$3.81M
derived: sum of 2 quarters · filed 2023-05-11
$6.48M
derived: sum of 3 quarters · filed 2023-05-11
$8.04M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$2.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22
$4.90M
derived: sum of 2 quarters · filed 2023-03-22
$6.46M
derived: sum of 3 quarters · filed 2023-03-22
$8.89M
10-K · filed 2023-03-22
2021-09-30$2.67M
10-Q · filed 2022-11-10
$2.81M
10-Q · filed 2021-11-10
$4.23M
derived: sum of 2 quarters · filed 2022-11-10
$6.66M
10-Q · filed 2022-11-10
$7.09M
10-Q · filed 2021-11-10
$7.12M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30$1.56M
10-Q · filed 2022-08-11
$1.66M
10-Q · filed 2021-08-12
$3.99M
10-Q · filed 2022-08-11
$4.28M
10-Q · filed 2021-08-12
$4.45M
derived: sum of 3 quarters · filed 2022-08-11
$5.71M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31$2.43M
10-Q · filed 2022-05-12
$2.62M
10-Q · filed 2021-05-13
$2.89M
derived: sum of 2 quarters · filed 2022-05-12
$4.15M
derived: sum of 3 quarters · filed 2022-05-12
$4.93M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31$463.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22
$1.72M
derived: sum of 2 quarters · filed 2022-03-22
$2.50M
derived: sum of 3 quarters · filed 2022-03-22
$3.72M
10-K · filed 2022-03-22
$4.43M
10-K · filed 2021-03-25
2020-09-30$1.26M
10-Q · filed 2021-11-10
$2.04M
derived: sum of 2 quarters · filed 2021-11-10
$3.25M
10-Q · filed 2021-11-10
$4.28M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30$779.00K
10-Q · filed 2021-08-12
$2.00M
10-Q · filed 2021-08-12
$3.02M
derived: sum of 3 quarters · filed 2021-08-12
$4.06M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31$1.22M
10-Q · filed 2021-05-13
$2.24M
derived: sum of 2 quarters · filed 2021-05-13
$3.28M
derived: sum of 3 quarters · filed 2021-05-13
$4.43M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31$1.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
$2.06M
derived: sum of 2 quarters · filed 2021-03-25
$3.21M
derived: sum of 3 quarters · filed 2021-03-25
$4.30M
10-K · filed 2021-03-25
2019-09-30$1.04M
10-Q · filed 2020-11-10
$2.19M
derived: sum of 2 quarters · filed 2020-11-10
$3.28M
10-Q · filed 2020-11-10
$4.22M
derived: sum of 4 quarters · filed 2020-11-10
2019-06-30$1.15M
10-Q · filed 2020-08-12
$2.23M
10-Q · filed 2020-08-12
$3.18M
derived: sum of 3 quarters · filed 2020-08-12
$4.02M
derived: sum of 4 quarters · filed 2020-08-12
2019-03-31$1.09M
10-Q · filed 2020-05-12
$2.03M
derived: sum of 2 quarters · filed 2020-05-12
$2.87M
derived: sum of 3 quarters · filed 2020-05-12
$4.05M
derived: sum of 4 quarters · filed 2020-05-12
2018-12-31$944.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26
$1.78M
derived: sum of 2 quarters · filed 2020-03-26
$2.96M
derived: sum of 3 quarters · filed 2020-03-26
$4.33M
10-K · filed 2020-03-26
2018-09-30$838.00K
10-Q · filed 2019-11-12
$2.02M
derived: sum of 2 quarters · filed 2019-11-12
$3.38M
10-Q · filed 2019-11-12
$4.59M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$1.18M
10-Q · filed 2019-08-12
$2.54M
10-Q · filed 2019-08-12
$3.75M
derived: sum of 3 quarters · filed 2019-08-12
$5.24M
derived: sum of 4 quarters · filed 2019-08-12
2018-03-31$1.36M
10-Q · filed 2019-05-14
$2.56M
derived: sum of 2 quarters · filed 2019-05-14
$4.05M
derived: sum of 3 quarters · filed 2019-05-14
$5.38M
derived: sum of 4 quarters · filed 2019-05-14
2017-12-31$1.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27
$2.69M
derived: sum of 2 quarters · filed 2019-03-27
$4.02M
derived: sum of 3 quarters · filed 2019-03-27
$5.37M
10-K · filed 2019-03-27
2017-09-30$1.49M
10-Q · filed 2018-11-14
$2.82M
derived: sum of 2 quarters · filed 2018-11-14
$4.17M
10-Q · filed 2018-11-14
$5.47M
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30$1.33M
10-Q · filed 2018-08-14
$2.68M
10-Q · filed 2018-08-14
$3.98M
derived: sum of 3 quarters · filed 2018-08-14
$5.45M
derived: sum of 4 quarters · filed 2018-08-14
2017-03-31$1.35M
10-Q · filed 2018-05-10
$2.65M
derived: sum of 2 quarters · filed 2018-05-10
$4.12M
derived: sum of 3 quarters · filed 2018-05-10
$5.46M
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31$1.31M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-26
$2.77M
derived: sum of 2 quarters · filed 2018-03-26
$4.11M
derived: sum of 3 quarters · filed 2018-03-26
$5.42M
10-K · filed 2018-03-26
2016-09-30$1.46M
10-Q · filed 2016-11-10
$2.80M
derived: sum of 2 quarters · filed 2018-03-26
$4.11M
10-Q/A · filed 2018-03-26
$5.83M
derived: sum of 4 quarters · filed 2018-03-26
2016-06-30$1.34M
10-Q/A · filed 2018-03-26
$2.64M
10-Q/A · filed 2018-03-26
$4.37M
derived: sum of 3 quarters · filed 2018-03-26
$6.10M
derived: sum of 4 quarters · filed 2018-03-26
2016-03-31$1.30M
10-Q/A · filed 2018-03-26
$3.03M
derived: sum of 2 quarters · filed 2018-03-26
$4.76M
derived: sum of 3 quarters · filed 2018-03-26
$6.12M
derived: sum of 4 quarters · filed 2018-03-26
2015-12-31$1.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30
$3.46M
derived: sum of 2 quarters · filed 2017-03-30
$4.82M
derived: sum of 3 quarters · filed 2017-03-30
$6.92M
10-K · filed 2017-03-30
2015-09-30$1.73M
10-Q · filed 2016-11-10
$3.10M
derived: sum of 2 quarters · filed 2016-11-10
$5.20M
10-Q · filed 2016-11-10
$6.76M
derived: sum of 4 quarters · filed 2016-11-10
2015-06-30$1.36M
10-Q · filed 2016-08-11
$3.47M
10-Q · filed 2016-08-11
$5.03M
derived: sum of 3 quarters · filed 2016-08-11
$6.49M
derived: sum of 4 quarters · filed 2016-08-11
2015-03-31$2.11M
10-Q · filed 2016-05-12
$3.67M
derived: sum of 2 quarters · filed 2016-05-12
$5.13M
derived: sum of 3 quarters · filed 2016-05-12
$6.31M
derived: sum of 4 quarters · filed 2016-05-12
2014-12-31$1.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30
$3.02M
derived: sum of 2 quarters · filed 2016-03-30
$4.20M
derived: sum of 3 quarters · filed 2016-03-30
$5.68M
10-K · filed 2016-03-30
2014-09-30$1.46M
10-Q · filed 2015-11-12
$2.64M
derived: sum of 2 quarters · filed 2015-11-12
$4.12M
10-Q · filed 2015-11-12
$5.56M
derived: sum of 4 quarters · filed 2015-11-12
2014-06-30$1.18M
10-Q · filed 2015-08-12
$2.66M
10-Q · filed 2015-08-12
$4.10M
derived: sum of 3 quarters · filed 2015-08-12
$5.33M
derived: sum of 4 quarters · filed 2015-08-12
2014-03-31$1.48M
10-Q · filed 2015-05-13
$2.91M
derived: sum of 2 quarters · filed 2015-05-13
$4.14M
derived: sum of 3 quarters · filed 2015-05-13
$5.36M
derived: sum of 4 quarters · filed 2015-05-13
2013-12-31$1.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
$2.67M
derived: sum of 2 quarters · filed 2015-03-30
$3.88M
derived: sum of 3 quarters · filed 2015-03-30
$17.65M
10-K · filed 2015-03-30
2013-09-30$1.23M
10-Q · filed 2014-11-13
$2.44M
derived: sum of 2 quarters · filed 2014-11-13
$16.21M
10-Q · filed 2014-11-13
$17.35M
derived: sum of 4 quarters · filed 2014-11-13
2013-06-30$1.21M
10-Q · filed 2014-08-14
$14.98M
10-Q · filed 2014-08-14
$16.12M
derived: sum of 3 quarters · filed 2014-08-14
$17.34M
derived: sum of 4 quarters · filed 2014-08-14
2013-03-31$13.77M
10-Q · filed 2014-05-14
$14.91M
derived: sum of 2 quarters · filed 2014-05-14
$16.12M
derived: sum of 3 quarters · filed 2014-05-14
$23.07M
derived: sum of 4 quarters · filed 2014-05-14
2012-12-31$1.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28
$2.35M
derived: sum of 2 quarters · filed 2014-03-28
$9.30M
derived: sum of 3 quarters · filed 2014-03-28
$10.45M
10-K · filed 2014-03-28
$56.18M
10-K · filed 2013-03-29
2012-09-30$1.21M
10-Q · filed 2013-11-14
$8.16M
derived: sum of 2 quarters · filed 2013-11-14
$9.31M
10-Q · filed 2013-11-14
$10.87M
derived: sum of 4 quarters · filed 2013-11-14
$55.05M
10-Q · filed 2012-11-13
2012-06-30$6.95M
10-Q · filed 2013-08-14
$8.10M
10-Q · filed 2013-08-14
$9.65M
derived: sum of 3 quarters · filed 2013-08-14
$10.78M
derived: sum of 4 quarters · filed 2013-08-14
$53.83M
10-Q · filed 2012-08-14
2012-03-31$1.15M
10-Q · filed 2013-05-15
$2.70M
derived: sum of 2 quarters · filed 2013-05-15
$3.83M
derived: sum of 3 quarters · filed 2013-05-15
$5.62M
derived: sum of 4 quarters · filed 2013-05-15
2011-12-31$1.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-29
$2.68M
derived: sum of 2 quarters · filed 2013-03-29
$4.47M
derived: sum of 3 quarters · filed 2013-03-29
$6.62M
10-K · filed 2013-03-29
2011-09-30$1.13M
10-Q · filed 2012-11-13
$2.92M
derived: sum of 2 quarters · filed 2012-11-13
$5.07M
10-Q · filed 2012-11-13
2011-06-30$1.79M
10-Q · filed 2012-08-14
$3.95M
10-Q · filed 2012-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
BIOVIE INC. (BIVI)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33